Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes
Pharmaceuticals · 13.08.2026 · 19 (8) · 1281
DOI: 10.3390/ph19081281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 13.08.2026. Verfasst von Siri Paulo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Science and Technology.
Abstract (Originalsprache)
Background/Objectives: Osteonecrosis of the jaw, a non-healing wound, is a side effect in patients treated with nitrogen-containing bisphosphonates (e.g., zoledronate) after some oral procedures. Considering zoledronate toxicity in surgical wounds and the capacity of calcium phosphate synthetic compounds to adsorb it, the aim of this work was to demonstrate and elucidate the mechanism underlying this adsorption.
Methods
Four different calcium phosphate synthetic bone substitutes were used in this study: AdBone® BCP (0.5–1 mm), Guidor® easy-graft (0.5–1 mm), Maxresorb® (0.5–1 mm) and Maxresorb® (0.8–1.5 mm). The materials were incubated in aqueous zoledronate solutions. Samples of the solutions obtained after 1, 2, 3, 6, 24, 48, 72 and 120 h of conditioning were then analyzed by spectrophotometry to measure their absorbance and subsequently characterized by micro-elemental analysis.
Results
All four materials demonstrated time-dependent zoledronate adsorption. AdBone® BCP achieved the most rapid and sustained sequestration, reaching 80% reduction at 24 h and stabilizing at 85% from 72 h onwards without re-release. Maxresorb® formulations showed comparable kinetics through 72 h (70–75%) but exhibited partial re-release at 120 h. Guidor® easy-graft showed negligible adsorption through the first 24 h, consistent with the physical barrier effect of its PLGA coating. Spectrophotometric findings were independently confirmed by elemental analysis.
Conclusions
This work confirms zoledronate adsorption by calcium phosphate synthetic biomaterials. Among the tested materials, AdBone® BCP demonstrated the most favorable adsorption profile, with kinetics well matched to the critical window of alveolar wound healing. These findings support the use of biphasic calcium phosphate bone substitutes as a local strategy to reduce free zoledronate bioavailability at the surgical site, potentially lowering the risk of MRONJ in patients undergoing dentoalveolar procedures under bisphosphonate therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
- Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal.
- Area of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.
- Clinical Academic Center of Coimbra (CACC), University of Coimbra, 3000-354 Coimbra, Portugal.
- Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
- Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
ORCID-Profile: Mafalda Laranjo, Ana Margarida Abrantes, Diogo A Fonseca, Maria Filomena Botelho, Manuel Marques Ferreira
Förderung
- Foundation for Science and Technology
Zitieren
APA
Paulo, S., Laranjo, M., Abrantes, A. M., Teixo, R. J., Fonseca, D. A., Mendes-Abreu, J., Figueiredo, J. P., Botelho, M. F., Ferreira, M. M., & Serra, A. (2026). Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes. Pharmaceuticals, 19(8), 1281. https://doi.org/10.3390/ph19081281
Vancouver
Paulo S, Laranjo M, Abrantes AM, Teixo RJ, Fonseca DA, Mendes-Abreu J, et al. Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes. Pharmaceuticals. 2026;19(8):1281. doi:10.3390/ph19081281
BibTeX
@article{Paulo2026,
author = {Paulo, Siri and Laranjo, Mafalda and Abrantes, Ana Margarida and Teixo, Ricardo Jorge and Fonseca, Diogo A and Mendes-Abreu, João and Figueiredo, José Pedro and Botelho, Maria Filomena and Ferreira, Manuel Marques and Serra, Arménio},
title = {Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1281},
doi = {10.3390/ph19081281}
}
EUVIMED